Insmed Inc. (NASDAQ:INSM) stock surged Thursday following a report that French pharmaceutical giant Sanofi SA (NASDAQ:SNY) is exploring a potential acquisition of the respiratory disease specialist.
The potential acquisition comes as Sanofi seeks new growth opportunities to reduce its reliance on blockbuster drug Dupixent.
Sanofi Explores Potential Insmed Takeover
Bloomberg reported Thursday that Sanofi is considering acquiring Insmed as it searches for its next blockbuster treatment under new CEO Belén Garijo.
Citing people familiar with the matter, the report said Sanofi is working with advisers to evaluate a potential deal.
Insmed's Commercial Drugs Drive Revenue Growth
Insmed has two commercial respiratory drugs: Brinsupri (brensocatib) and Arikayce (amikacin liposome inhalation suspension).
Brinsupri treats non-cystic fibrosis bronchiectasis, while Arikayce treats refractory Mycobacterium avium complex (MAC) lung disease.
In the third quarter, Brinsupri generated sales of $400.1 million, while Arikayce sales reached $124.4 million.
Insmed expects 2026 Brinsupri revenue of $1.35 billion to $1.4 billion. Meanwhile, the company forecasts Arikayce sales of $460 million to $470 million.
Insmed Advances Respiratory Drug Pipeline
Insmed is also developing treprostinil palmitil inhalation powder (TPIP) for four lung disease indications. Its early-stage pipeline includes INS1148, INS1033 and next-generation DPP1 inhibitors.
In July, Insmed reported 12-month results from an ongoing open-label extension study of TPIP in patients with pulmonary arterial hypertension.
The data showed sustained improvements across multiple efficacy measures. Patients who switched from placebo to TPIP experienced similar benefits.
In March, Insmed reported topline results from its Phase 3b ENCORE study of Arikayce. The treatment, combined with multidrug therapy, met the study's primary and all secondary endpoints.
The results highlighted Arikayce's potential to benefit patients with MAC lung infections.
Meanwhile, Insmed Chief Financial Officer Sara Bonstein stepped down on Oct. 30 after nearly seven years in the role.
Sanofi Seeks Growth Beyond Dupixent
Bloomberg noted that Sanofi investors are awaiting a major acquisition involving a late-stage drug candidate. Such a deal could help offset potential revenue losses when Dupixent, its blockbuster treatment for inflammatory conditions, including eczema and asthma, loses patent protection.
"Garijo has just taken over, but the drugmaker's challenge remains the same — driving a step change in a historically underperforming R&D organization and delivering new growth sources to support Dupixent," Bloomberg Intelligence analysts John Murphy and Aude Gerspacher wrote.
Sanofi Tightens Research and Development Strategy
During its second-quarter earnings call, Sanofi signaled a more disciplined approach to research and development.
Garijo attributed recent pipeline setbacks to weak decision-making rather than shortcomings in the company's scientific capabilities.
She also highlighted an ongoing portfolio review and did not rule out discontinuing additional drug candidates.
Sanofi aims to prioritize medicines with the strongest scientific merit, highest unmet medical need and greatest commercial potential.
INSM/SNY Price Action: Insmed shares were up 18.43% at $141.87 and Sanofi shares were down 2.05% at $46.15 at the time of publication on Thursday, according to market data.